Drug Discovery and Development Solutions for Lymphoma

Our In Vitro Efficacy Testing Service accelerates lymphoma drug discovery by providing comprehensive, sensitive platforms for screening and characterizing therapeutic candidates. Utilizing advanced cell-based, biochemical, and biophysical assays, we evaluate compound efficacy against key lymphoma targets, including PD-1/PD-L1, Bcl-2 family proteins, and signaling mediators. Core methodologies include flow cytometry, ELISA, FRET, chemiluminescence, and surface plasmon resonance. We deliver critical pharmacological parameters—IC-50, EC-50, Kd, Ki, and MIC—enabling robust comparison and optimization of drug candidates. Our tailored approach ensures high-quality, actionable data, supporting informed decision-making throughout preclinical lymphoma therapy development.

Protheragen offers comprehensive in vivo lymphoma animal model development services, utilizing a portfolio of 160 validated murine models across 27 strains. We provide xenograft, syngeneic, allograft, and genetically engineered models, enabling robust evaluation of anti-lymphoma agents and mechanistic studies. Our end-to-end solutions encompass model selection or customization, cell line or PDX engraftment, study design, treatment, and advanced endpoint analyses including imaging, flow cytometry, and biomarker assessment. Rigorous quality control ensures data reliability. With deep expertise and adaptable platforms, Protheragen accelerates preclinical research, supporting drug discovery and translational objectives for lymphoma therapeutics.

Our PK/PD research service for Lymphoma provides comprehensive analysis of drug exposure and response using advanced analytical techniques such as HPLC, LC-MS, and ELISA. We support multiple administration routes and analyze key biological compartments, including blood, lymph nodes, and tumor tissues. With access to diverse animal models, our studies deliver critical insights into ADME properties, concentration-effect relationships, and optimal dosing strategies. Our integrated approach ensures high-quality, reproducible data, enabling informed decisions throughout Lymphoma drug development. Partner with us to advance your preclinical and translational research with robust, actionable data and expert scientific guidance at every stage.

Protheragen’s Toxicity Assessment Service for lymphoma therapeutics provides comprehensive in vivo safety evaluations, supporting all stages of preclinical development. Utilizing advanced analytical technologies, diverse animal models, and validated protocols, we conduct acute, chronic, organ-specific, systemic, and special toxicology studies. Our methodologies include high-throughput histopathology, flow cytometry, and digital monitoring, ensuring rigorous data integrity and regulatory compliance. By integrating disease-relevant endpoints such as immunophenotyping and tumor burden assessment, we deliver actionable insights into candidate safety profiles. This enables informed decision-making and risk mitigation, empowering the advancement of innovative lymphoma treatments with confidence and scientific rigor.

Protheragen offers specialized biomarker analysis services supporting Lymphoma research through multi-omics discovery strategies and advanced analytical platforms. We explore and screen molecular candidates using genomics, proteomics, transcriptomics, and metabolomics approaches, assessing their potential as biomarkers relevant to Lymphoma pathophysiology. Our methodologies encompass high-throughput screening, candidate evaluation, and assay development across immunoassays, mass spectrometry, flow cytometry, and molecular diagnostics. Emphasizing rigorous analytical standards, we investigate and characterize biomarker candidates to facilitate data-driven insights for preclinical research. Our expertise enables comprehensive evaluation of molecular targets, supporting the exploration of disease mechanisms and potential therapeutic avenues in Lymphoma.